# PMV Pharmaceuticals (PMVP) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/PMVP
## Company Profile
- Ticker: PMVP
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: Small Molecule Drugs, Oncology
## Stock Data
- Close: 1.3 USD
- Market cap: 62931483.879999995 USD
- Last updated: 2026-08-11
## Business Overview
### Mutant p53 Precision Oncology
PMV Pharmaceuticals develops small molecules that restore activity to specific mutant forms of the tumor suppressor p53.
### Rezatapopt
Rezatapopt selectively binds the TP53 Y220C mutant and is designed to restore wild-type p53 structure and tumor-suppressor function.
### Ovarian Cancer Lead Indication
The PYNNACLE program is focused on platinum-resistant or refractory ovarian cancer carrying TP53 Y220C, with broader solid-tumor development also underway.
## Why The Stock Is Moving

As of Aug 11, 2026, PMVP closed up 5.69% at $1.30. No new same-company headline was identified in the current news window.

## Future Catalysts

- PMV plans to submit an NDA for rezatapopt in TP53 Y220C-positive platinum-resistant or refractory ovarian cancer in the first quarter of 2027.

## Recent News
- 2026-05-12 12:00 EST — [PMV Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-first-quarter-2026-financial-results-and-corporate-highlights) — Source: PMV Pharmaceuticals
- 2026-04-22 12:00 EST — [PMV Pharmaceuticals Announces Board Chair Transition](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-announces-board-chair-transition) — Source: PMV Pharmaceuticals
- 2026-03-06 13:00 EST — [PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-full-year-2025-financial-results-and-corporate-highlights) — Source: PMV Pharmaceuticals
- 2026-02-26 13:00 EST — [New England Journal of Medicine Publishes First-in-Human Rezatapopt Data Showing Selective Reactivation of Mutant p53 in Advanced Solid Tumors](https://biopharmsignal.com/news/PMVP/new-england-journal-of-medicine-publishes-first-in-human-rezatapopt-data-showing-selective-reactivation-of-mutant-p53-in-advanced-solid-tumors) — Source: PMV Pharmaceuticals
- 2025-11-12 13:01 EST — [PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights](https://biopharmsignal.com/news/PMVP/pmv-pharmaceuticals-reports-third-quarter-2025-financial-results-and-corporate-highlights) — Source: PMV Pharmaceuticals